SVI takes next step in Alzheimer's research collaboration with Janssen

29 August 2019
janssen-big-1

St Vincent’s Institute of Medical Research (SVI) in Melbourne, Australia, today announced the extension of the research and licensing collaboration agreement with Janssen Pharmaceuticals, part of US healthcare giant Johnson & Johnson (NYSE: JNJ), with focus on Alzheimer’s disease treatment.

The objective of the initiative is to develop and potentially commercialize small molecule modulators of microglial function and inflammation. The collaboration was facilitated by Johnson & Johnson Innovation.

Janssen takes up option

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Pharmaceutical